{"record_key":"targeting-ntpdase8-for-treating-liver-ischemia","identifier":"CU25127","external_key":"CU25127","title":"Treating liver ischemia-reperfusion with NTPDase8","summary":null,"url":"https://inventions.techventures.columbia.edu/technologies/treating-liver-ischemia--CU25127","json_url":"https://inventions.techventures.columbia.edu/technologies/treating-liver-ischemia--CU25127.json","object_key":"technologies","description":"This technology describes the use of nucleoside triphosphate diphosphohydrolases (NTPDase8) for the treatment of liver ischemia-reperfusion injury.\nUnmet Need: Targeted therapies for liver ischemia-reperfusion injury\nLiver ischemia-reperfusion (I/R) injury occurs when the blood supply to the liver is temporarily disrupted and then restored, causing significant hepatic parenchymal damage. This injury frequently occurs during liver transplantation, substantive liver resections, and following trauma. The pathogenesis of liver I/R injury is complex, and involves a cascade of cellular and molecular events that ultimately lead to tissue damage. Despite the long-term implications of this injury, there are limited treatment options that target the molecular events leading to liver I/R tissue damage.\nThe Technology: NTPDase8 for treating liver ischemia-reperfusion injury\nThis technology describes the administration of NTPDase8 for the treatment of liver ischemia-reperfusion injury. NTPDase8 serves a protective role in the liver by critically suppressing inflammatory and metabolic responses to liver ischemia-reperfusion (I/R) injury. By modulating the extracellular levels of purine nucleotides and nucleosides, NTPDase8 reduces hepatic injury after I/R. Exogenous administration or endogenous overexpression of NTPDase8 therefore represents a strategy for preventing or treating liver I/R injury.\nThis technology has been validated in models of liver I/R injury in vivo.\nApplications:\nSystemic hypotension/shock (e.g., massive hemorrhage, sepsis, cardiac failure)\nPortal occlusion during major liver surgeries\nReperfusion of donor liver allografts in transplantation\nAdvantages:\nTargets molecular events leading to liver I/R injury\nApplicable to several pathological conditions\nPotential first-in-class therapeutic agent\nLead Inventor:\nGeorge Hasko, M.D., Ph.D: https://www.anesthesiology.cuimc.columbia.edu/research-labs/hasko-lab\nPatent Information:\nPatent Pending (WO/2026/183317: https://globaldossier.uspto.gov/result/publication/CASE/WO2026183317/69596)\nRelated Publications:\nKelestemur T, Robson SC, Németh ZH, Pacher P, Arif M, Aydin MS, Suzek BE, Pelletier J, Lunsford KE, Schwabe RF, Geng Y, Sévigny J, Haskó G. “NTPDase8 Protects Against Liver Ischemia-Reperfusion Injury in Mice.” FASEB J. 2025 Jul 15;39(13):e70775.: https://pubmed.ncbi.nlm.nih.gov/40600918/\nTech Ventures Reference:\nIR CU25127\nLicensing Contact: Kristin Neuman: mailto:techtransfer@columbia.edu","attributes":[{"key":"tags","label":"Tags","values":["Pathogenesis","Hypotension","Purine","Ischemia","Epistasis","Nucleotide","Vascular occlusion","Heart failure","Bleeding","Allotransplantation","Nucleoside triphosphate","Liver","Sepsis"]},{"key":"inventors","label":"Inventors","values":["George Hasko","Taha Kelestemur"]},{"key":"manager","label":"Manager","values":["Kristin Neuman"]},{"key":"depts","label":"Departments","values":["Anesthesiology"]},{"key":"divs","label":"Divisions","values":["Columbia University Medical Center (CUMC)"]},{"key":"file_number","label":"File Number","values":["CU25127"]},{"key":"date_released","label":"Release Date","values":["Oct 16, 2025"]}],"related":[]}